SCHEMBL8095461

SCHEMBL8095461

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@@H](C)CNC(=O)C[C@](C)(O)C(F)(F)F)CC[C@@H]23)C[C@@H](O)C[C@@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 13/20 0.66
▸ MAPT P10636 2/20 0.65
▸ ADORA3 P0DMS8 2/20 0.65
▸ SLC6A2 P23975 2/20 0.65
▸ AGTR1 P30556 2/20 0.65
▸ NR1I2 O75469 1/20 0.65
▸ ABCB11 O95342 1/20 0.65
▸ GC P02774 1/20 0.65
▸ PGR P06401 1/20 0.65
▸ RXRA P19793 1/20 0.65
▸ CHRM3 P20309 1/20 0.65
▸ CNR1 P21554 1/20 0.65
▸ HTR2C P28335 1/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ SLC6A4 P31645 1/20 0.65
▸ ADRA1A P35348 1/20 0.65
▸ PTGS2 P35354 1/20 0.65
▸ OPRD1 P41143 1/20 0.65
▸ OPRK1 P41145 1/20 0.65
▸ SLC6A3 Q01959 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8091708 1.00 VDR (0.66) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8095463 1.00 VDR (0.66) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8091711 1.00 VDR (0.66) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8091767 0.90 MAPT (0.65) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8091769 0.90 MAPT (0.65) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8091703 0.90 MAPT (0.65) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8091706 0.90 MAPT (0.65) VDRMAPTADORA3SLC6A2AGTR1
SCHEMBL8090213 0.88 VDR (0.62) VDRCYP24A1
SCHEMBL8090198 0.88 VDR (0.62) VDRCYP24A1
SCHEMBL8090209 0.88 VDR (0.62) VDRCYP24A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6043385-A TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM HOFFMAN-LA ROCHE INC. (US) 2000-03-28 — — US claimed
US-6043385-A TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM HOFFMAN-LA ROCHE INC. (US) 2000-03-28 — — US disclosed
Send feedback